With your own knowledge and the help of the following document:

Document 1 (Title: Antiepileptic Drug Interactions: Clinical Implications): Phenytoin represents a widely utilized antiepileptic medication with substantial potential for clinically significant drug interactions requiring careful consideration during concurrent medication administration. Hormonal contraceptive efficacy demonstrates particularly concerning interactions with phenytoin therapy, with multiple case reports and pharmacokinetic studies documenting contraceptive failure during concomitant use. This interaction primarily results from phenytoin's cytochrome P450 induction accelerating contraceptive steroid metabolism, potentially reducing hormonal concentrations below therapeutic thresholds. Practitioners regularly observe reduced contraceptive efficacy necessitating alternative contraceptive approaches for female patients requiring phenytoin therapy. Antimicrobial combinations represent another clinically important interaction category, with trimethoprim-sulfamethoxazole co-administration resulting in significant phenytoin metabolism inhibition through competition for cytochrome P450 catalytic sites. This interaction produces potential toxicity through elevated phenytoin concentrations, requiring either dosage adjustment or alternative antimicrobial selection. Notably, certain histamine-2 receptor antagonists including cimetidine similarly inhibit phenytoin metabolism through cytochrome P450 inhibition, potentially precipitating toxicity with manifestations including nystagmus, ataxia, and cognitive impairment when administered concurrently without appropriate dosage modification. Antifungal therapies demonstrate variable interaction potential, with certain azole compounds significantly affecting phenytoin pharmacokinetics while other antifungals including griseofulvin exhibit minimal interaction potential, with limited documented effect on phenytoin concentrations despite theoretical metabolism-based concerns. Beta-lactam antibiotics including ampicillin demonstrate similar pharmacokinetic compatibility, with minimal documented alterations in phenytoin concentrations during co-administration, allowing their concurrent use without specific dosage adjustments. These variable interaction profiles necessitate individualized medication selection based on specific clinical scenarios, potential alternative agents, and monitoring capabilities.
Document 2 (Title: Clinical Applications of Combined Antimicrobial Agents): Co-trimoxazole represents a widely utilized antimicrobial combination with distinctive pharmacological properties determining its clinical applications and safety considerations. Formulation analysis confirms this agent comprises a fixed combination of sulfamethoxazole and trimethoprim, typically in a 5:1 ratio, creating a synergistic antibacterial effect through sequential inhibition of bacterial folate synthesis. This combination demonstrates particular therapeutic efficacy against Toxoplasma gondii, establishing it as a mainstay treatment for toxoplasmosis across various clinical presentations including cerebral, ocular, and congenital infections. The synergistic mechanism involves sulfamethoxazole inhibition of dihydropteroate synthetase followed by trimethoprim inhibition of dihydrofolate reductase rather than dihydrofolate synthetase, creating a sequential blockade of distinct steps in the folate synthesis pathway. Adverse effect profiles include potentially severe cutaneous reactions ranging from mild rashes to life-threatening conditions including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome), particularly in specific risk groups including HIV-infected individuals. Significant drug interactions necessitate careful prescribing considerations, with concurrent methotrexate administration specifically contraindicated due to additive antifolate effects potentially resulting in severe bone marrow suppression and other toxicities. This interaction occurs through both agents affecting folate metabolism through different mechanisms, with trimethoprim inhibiting dihydrofolate reductase activity necessary for methotrexate clearance. The pharmacokinetic profile demonstrates good oral absorption and extensive tissue distribution, including cerebrospinal fluid penetration explaining its utility in central nervous system infections. These characteristics collectively inform appropriate clinical applications, dosing considerations, monitoring requirements, and contraindications for this widely utilized antimicrobial agent across diverse infectious disease scenarios.
Document 3 (Title: Infectious Complications and Management of Mammalian Bites): Mammalian bite wounds represent a significant cause of emergency department visits, with dog bites accounting for 80-90% of all reported cases. While immediate traumatic complications demand attention, infection risk represents the principal concern guiding therapeutic decision-making. The infectious risk varies substantially by biting species, wound characteristics, and host factors. Canine bite wounds typically demonstrate polymicrobial infections reflecting the dog's oral flora, with Pasteurella species (particularly P. canis), Staphylococcus, Streptococcus, Capnocytophaga canimorsus, and anaerobes including Bacteroides, Fusobacterium, and Porphyromonas predominating. Several factors influence infection risk, including wound location (hand bites carrying 3-4 fold higher risk), wound type (puncture wounds posing greater risk than lacerations), host immunocompetence, and time to medical attention. Wounds sustained during aggressive interactions, particularly those occurring while animals are feeding, demonstrate particularly high inoculation burdens. Initial management centers on thorough irrigation and debridement, with high-pressure irrigation (5-8 psi) using normal saline or tap water effectively reducing bacterial inoculum. Wound closure decisions require individualized assessment, with primary closure generally avoided for high-risk wounds including punctures, hand injuries, wounds with established infection, and those presenting beyond 12 hours post-injury. Prophylactic antibiotics are recommended for higher-risk wounds, with amoxicillin-clavulanic acid representing the consensus first-line agent due to its efficacy against both aerobic and anaerobic components of the typical polymicrobial inoculum, including beta-lactamase producing organisms. Alternative regimens for penicillin-allergic patients include trimethoprim-sulfamethoxazole or doxycycline plus clindamycin, though these combinations provide less reliable anaerobic coverage. Tetanus prophylaxis should be administered according to standard guidelines, with rabies risk assessment conducted for all mammalian bites.

Answer the following list question.
Question: Select the medication association(s) not recommended with phenytoin:
Options:
1. Estrogen-progestin contraceptives
2. Griseofulvin
3. Sulfamethoxazole combined with trimethoprim
4. Cimetidine
5. Ampicillin

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ‚Üê if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.